Its main job is to act as a kind of cellular delivery service: it transports long-chain fatty acids into the mitochondria the tiny power plants inside your cells where those fats are oxidized to produce energy
Semaglutide is administered via an injection under the skin once a week
Moderated by Tony Giordano (NYC Board of Education Retirement System), the panel featured Dylan Tate, CFA, CAIA, CIPM (NYSNA Pension Plan & Benefits Fund), Cedric Fan (Russell Investments), Chris Anderson (TIFF Investment Management), and Han Yik (NYSTRS)
Tirzepatide: This dual agonist of GLP-1 and GIP delivers superior glycemic control and weight reduction, setting it apart as the latest innovation in this drug class

article/pii/S0140673624014983 [Additional references continue covering all cited sources from the searches conducted] [1] Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial ScienceDirect science/article/pii/S0140673624014983 [2] The SELECT trial of semaglutide in patients with overweight or obesity without diabetes: establishing a new pathway to secondary prevention of cardiovascular disease PubMed pubmed.ncbi.nlm.nih.gov [3] Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial PubMed pubmed.ncbi.nlm.nih.gov [4] Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial PubMed pubmed.ncbi.nlm.nih.gov [5] GLP-1 receptor agonists: A novel pharmacotherapy for binge eating (Binge eating disorder and bulimia nervosa)
